<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362731">
  <stage>Registered</stage>
  <submitdate>9/07/2012</submitdate>
  <approvaldate>10/07/2012</approvaldate>
  <actrnumber>ACTRN12612000734864</actrnumber>
  <trial_identification>
    <studytitle>Effect of Fenofibrate on Endothelial Dysfunction and Oxidative Stress in patients with Type 2 Diabetes Mellitus:  an open label study</studytitle>
    <scientifictitle>Effect of Fenofibrate on Endothelial Dysfunction and Oxidative Stress in patients with Type 2 Diabetes Mellitus:  an open label study</scientifictitle>
    <utrn>U1111-1132-5269</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>type 2 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>to investigate the role of fenofibrate on plasma myeloperoxidase concentrations in patients with type 2 diabetes.
Starting from visit 1, each subject received daily treatment with oral tablets of fenofibrate 160 mg once daily for 8 weeks.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the effect of fenofibrate treatment on plasma myeloperoxidase measured  in plasma (EDTA) using commercial enzyme-linked immunosorbent assay kits for quantitative detection: plasma MPO (DRG International, Inc, USA).</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the effect of fenofibrate treatment on E-selectin measured  in plasma (EDTA) using commercial enzyme-linked immunosorbent assay kits for quantitative detection: sE-selectin (DRG Diagnostics GmbH, Germany)</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>the effect of fenofibrate treatment on flow mediated dilation</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with type 2 diabetes
treated with metformin monotherapy
without previous diagnosis of dyslipidemia and/or use of lipid-lowering medication</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>type 1 diabetes mellitus
treatment with other hypoglycaemic drugs in the past 3 months,
recent acute cardiovascular event within 3 months, 
uncontrolled endocrine or metabolic diseases
chronic kidney disease 
persistent elevation of alanine aminotransferase, aspartate aminotransferase, 
history of alcohol abuse, 
previous treatment with any lipid-lowering drugs, 
changes  in hypoglycaemic or antihypertensive treatment during the last 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/05/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>27</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Nita Cristina</primarysponsorname>
    <primarysponsoraddress>2-4 Clinicilor Street
400006
Cluj Napoca</primarysponsoraddress>
    <primarysponsorcountry>Romania</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Romania</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Fenofibrate is a drug largely used in patients with type 2 diabetes and mixed dyslipidemia due to its effects of reducing triglycerides concentration and enhancing HDL cholesterol levels. Also there are a lot of evidences regarding the pleiotropic effects of fenofibrate such as: decrease in systemic inflammation and monocyte cytokine release, improvement in insulin sensitivity and hemostasis,  important antioxidant, antithrombotic and antiplatelet activities.
In light of the foregoing data, the main purpose of this study was to investigate the role of fenofibrate on plasma MPO concentrations in patients with type 2 diabetes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of the "iuliu Hatieganu" University of Medicine and Pharmacy</ethicname>
      <ethicaddress>13 Emil Isac street
400023 Cluj Napoca</ethicaddress>
      <ethicapprovaldate>26/10/2010</ethicapprovaldate>
      <hrec>180/26-10-2010</hrec>
      <ethicsubmitdate>20/08/2010</ethicsubmitdate>
      <ethiccountry>Romania</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Cristina Nita</name>
      <address>2-4 Clinicilor street
Cluj Napoca
400006</address>
      <phone>+40744549928</phone>
      <fax />
      <email>cnita@umfcluj.ro</email>
      <country>Romania</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Cristina Nita</name>
      <address>2-4 Clinicilor street
Cluj Napoca
400006</address>
      <phone>+40744549928</phone>
      <fax />
      <email>cnita@umfcluj.ro</email>
      <country>Romania</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>